拡張型心筋症治療薬市場：薬剤クラス別、治療タイプ別、投与経路別、エンドユーザー別、流通チャネル別-2025-2030年の世界予測

拡張型心筋症治療薬市場は、2023年に4億2,150万米ドルと評価され、2024年には4億5,676万米ドルに達すると予測され、CAGR 7.79%で成長し、2030年には7億1,265万米ドルに達すると予測されています。

拡張型心筋症（DCM）治療薬は、心臓の肥大と弱体化を特徴とする心筋疾患である拡張型心筋症の状態を管理・緩和することを目的とした標的治療戦略および薬剤に関連します。拡張型心筋症治療薬の必要性は、世界の心臓病有病率の増加、高齢化人口の増加、患者のQOLと生存率を改善する専門的治療の必要性によって強調されています。これらの治療薬の適用には通常、ACE阻害薬やβ遮断薬などの薬理学的介入が含まれ、場合によっては機械的装置の使用や心臓移植も行われます。最終用途の範囲には主に、高度な心臓治療を専門とする病院、診療所、学術医療センターが含まれます。主な市場成長要因としては、医療機器の技術的進歩、ヘルスケア支出の増加、心筋症に対する認識と診断率の向上などが挙げられます。遺伝子治療や幹細胞治療などの新規治療に焦点を当てた研究開発活動の活発化は、市場参入企業にとってポートフォリオを拡大する潜在的な機会となります。戦略的提携やパートナーシップと相まって、新興市場での地理的拡大も未開拓市場を活用する機会を提供しています。しかし、高額な治療費、厳しい規制状況、副作用の可能性といった制約が、市場成長にとって大きな課題となる可能性があります。さらに、心筋症の複雑な病態生理が治療開発を困難にしており、多額の研究開発投資が必要となります。イノベーションと事業成長を促進するために、ゲノムおよびバイオマーカー研究、精密医療、非侵襲的診断法、遠隔医療などの分野が、DCM治療薬の分野で大きなブレークスルーをもたらす可能性があります。市場はダイナミックで競争が激しいため、企業は俊敏かつ革新的であり続ける必要があり、競争優位に立つためには患者中心のアプローチに注力する必要があります。臨床試験、技術の進歩、規制の継続的なモニタリングは、この複雑な状況を乗り切り成功を目指す利害関係者にとって極めて重要です。

市場力学：急速に進化する拡張型心筋症治療薬市場の主要市場インサイトを公開

拡張型心筋症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 心血管疾患の流行と効果的な治療の必要性
  • 疾患の早期診断と治療への志向
  • 心血管疾患に関する認識を高めるための政府の取り組みとプログラム
• 市場抑制要因
  • 拡張型心筋症治療薬の高コスト
• 市場機会
  • 拡張型心筋症の管理における精密医療の応用
  • 拡張型心筋症に対する効率的な薬剤や治療法の開発のための継続的な研究開発
• 市場の課題
  • 拡張型心筋症治療薬に伴う副作用

ポーターのファイブフォース：拡張型心筋症治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：拡張型心筋症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、拡張型心筋症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析拡張型心筋症治療薬市場における競合情勢の把握

拡張型心筋症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス拡張型心筋症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、拡張型心筋症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨拡張型心筋症治療薬市場における成功への道筋を描く

拡張型心筋症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 心血管疾患の蔓延と効果的な治療の必要性
    • 病気の早期診断と治療への傾向
    • 心血管疾患に関する意識を高めるための政府の取り組みとプログラム
  • 抑制要因
    • 拡張型心筋症治療薬の高コスト
  • 機会
    • 拡張型心筋症の管理における精密医療の応用
    • 拡張型心筋症に対する有効な薬剤と治療法の開発に向けた継続的な研究開発
  • 課題
    • 拡張型心筋症治療薬に伴う副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 拡張型心筋症治療薬市場薬剤クラス別

• アルドステロン拮抗薬
• アンジオテンシンII受容体遮断薬
• アンジオテンシン変換酵素（ACE）阻害剤
• ベータ遮断薬

第7章 拡張型心筋症治療薬市場治療の種類別

• 除細動器
• 心臓ポンプ
• 埋め込み型デバイス
• 薬物治療

第8章 拡張型心筋症治療薬市場：投与経路別

• オーラル
• 非経口

第9章 拡張型心筋症治療薬市場：エンドユーザー別

• 病院
• 調査機関
• 専門クリニック

第10章 拡張型心筋症治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカの拡張型心筋症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の拡張型心筋症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの拡張型心筋症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Amicus Therapeutics
• Astellas Pharma Inc
• AstraZeneca plc
• Bayer AG
• Biogen Inc.
• BioMarin Pharmaceutical Inc
• C.H. Boehringer Sohn AG & Co. KG
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• Gilead Sciences, Inc.
• GlaxoSmithKline（GSK）
• Johnson & Johnson Services, Inc.
• Kyowa Kirin Co, Ltd
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Sanofi S.A.
• Sarepta Therapeutics
• Teva Pharmaceutical Industries Ltd.
• The Bristol-Myers Squibb Company
• The Takeda Pharmaceutical Company Limited
• Vertex Pharmaceuticals
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 78. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 163. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 183. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 188. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 238. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Dilated Cardiomyopathy Therapeutics Market was valued at USD 421.50 million in 2023, expected to reach USD 456.76 million in 2024, and is projected to grow at a CAGR of 7.79%, to USD 712.65 million by 2030.

Dilated Cardiomyopathy (DCM) Therapeutics pertains to the targeted treatment strategies and medications aimed at managing and mitigating the condition of dilated cardiomyopathy, a heart muscle disease characterized by an enlarged and weakened heart. The necessity of DCM therapeutics is underscored by the increasing prevalence of heart diseases globally, rising aging populations, and the need for specialized treatments that improve quality of life and survival rates for patients. Application of these therapeutics typically involves pharmacological interventions such as ACE inhibitors, beta-blockers, and in some cases, the use of mechanical devices or even heart transplants. The end-use scope primarily includes hospitals, clinics, and academic medical centers dedicated to advanced cardiac care. Key market growth factors include technological advancements in medical devices, increasing healthcare expenditure, and growing awareness and diagnosis rates of cardiomyopathies. Rising R&D activities focused on novel therapies such as gene and stem cell therapy offer potential opportunities for market players to expand their portfolio. Geographical expansion in emerging markets, coupled with strategic collaborations and partnerships, also present opportunities to capitalize on untapped markets. However, limitations such as high costs of treatment, strict regulatory landscapes, and the potential for adverse drug reactions can pose significant challenges to market growth. Moreover, the complex pathophysiology of cardiomyopathies makes treatment development challenging, requiring significant R&D investments. To foster innovation and business growth, areas like genomic and biomarker research, precision medicine, non-invasive diagnostic methods, and telemedicine could yield substantial breakthroughs in the field of DCM therapeutics. The market is dynamic and competitive, requiring companies to stay agile and innovative, focusing on patient-centric approaches to gain a competitive edge. Continuous monitoring of clinical trials, technological advancements, and regulations will be crucial for stakeholders aiming to navigate and succeed in this complex landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dilated Cardiomyopathy Therapeutics Market

The Dilated Cardiomyopathy Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of cardiovascular diseases and the need for effective treatments
  • Inclination toward early diagnosis and treatment of diseases
  • Government initiatives and programs to raise awareness regarding cardiovascular diseases
• Market Restraints
  • High cost of dilated-cardiomyopathy therapeutics
• Market Opportunities
  • Applications of precision medicine in the management of dilated cardiomyopathy
  • Ongoing R&D for the development of efficient drugs and therapies for dilated-cardiomyopathy
• Market Challenges
  • Side effects associated with the dilated-cardiomyopathy medications

Porter's Five Forces: A Strategic Tool for Navigating the Dilated Cardiomyopathy Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dilated Cardiomyopathy Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dilated Cardiomyopathy Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dilated Cardiomyopathy Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dilated Cardiomyopathy Therapeutics Market

A detailed market share analysis in the Dilated Cardiomyopathy Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dilated Cardiomyopathy Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dilated Cardiomyopathy Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dilated Cardiomyopathy Therapeutics Market

A strategic analysis of the Dilated Cardiomyopathy Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dilated Cardiomyopathy Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amicus Therapeutics, Astellas Pharma Inc, AstraZeneca plc, Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc, C.H. Boehringer Sohn AG & Co. KG, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline (GSK), Johnson & Johnson Services, Inc., Kyowa Kirin Co, Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sarepta Therapeutics, Teva Pharmaceutical Industries Ltd., The Bristol-Myers Squibb Company, The Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Dilated Cardiomyopathy Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug class, market is studied across Aldosterone antagonists, Angiotensin II Receptor Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, and Beta-blockers.
• Based on Treatment Type, market is studied across Cardioverter-Defibrillators, Heart Pumps, Implantable Devices, and Medication.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on End-User, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of cardiovascular diseases and the need for effective treatments
    • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
    • 5.1.1.3. Government initiatives and programs to raise awareness regarding cardiovascular diseases
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of dilated-cardiomyopathy therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Applications of precision medicine in the management of dilated cardiomyopathy
    • 5.1.3.2. Ongoing R&D for the development of efficient drugs and therapies for dilated-cardiomyopathy
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with the dilated-cardiomyopathy medications
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dilated Cardiomyopathy Therapeutics Market, by Drug class

• 6.1. Introduction
• 6.2. Aldosterone antagonists
• 6.3. Angiotensin II Receptor Blockers
• 6.4. Angiotensin-converting enzyme (ACE) Inhibitors
• 6.5. Beta-blockers

7. Dilated Cardiomyopathy Therapeutics Market, by Treatment Type

• 7.1. Introduction
• 7.2. Cardioverter-Defibrillators
• 7.3. Heart Pumps
• 7.4. Implantable Devices
• 7.5. Medication

8. Dilated Cardiomyopathy Therapeutics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Dilated Cardiomyopathy Therapeutics Market, by End-User

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Research Institutes
• 9.4. Specialty Clinics

10. Dilated Cardiomyopathy Therapeutics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacy
• 10.3. Online Pharmacy
• 10.4. Retail Pharmacy

11. Americas Dilated Cardiomyopathy Therapeutics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Dilated Cardiomyopathy Therapeutics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Dilated Cardiomyopathy Therapeutics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Amicus Therapeutics
• 4. Astellas Pharma Inc
• 5. AstraZeneca plc
• 6. Bayer AG
• 7. Biogen Inc.
• 8. BioMarin Pharmaceutical Inc
• 9. C.H. Boehringer Sohn AG & Co. KG
• 10. Daiichi Sankyo Company, Limited
• 11. Eli Lilly and Company
• 12. Gilead Sciences, Inc.
• 13. GlaxoSmithKline (GSK)
• 14. Johnson & Johnson Services, Inc.
• 15. Kyowa Kirin Co, Ltd
• 16. Merck & Co., Inc.
• 17. Novartis AG
• 18. Pfizer Inc.
• 19. Regeneron Pharmaceuticals, Inc.
• 20. Roche Holding AG
• 21. Sanofi S.A.
• 22. Sarepta Therapeutics
• 23. Teva Pharmaceutical Industries Ltd.
• 24. The Bristol-Myers Squibb Company
• 25. The Takeda Pharmaceutical Company Limited
• 26. Vertex Pharmaceuticals
• 27. Viatris Inc.